Articles On Noxopharm (ASX:NOX)

Noxopharm (ASX:NOX) has announced that its lead oncology drug candidate Veyonda has been granted Orphan Drug Designation by the US FDA for its use in the treatment of soft tissue sarcoma.

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX to rise, but Wall Street falters on J Powell commments US stocks fell slightly overnight as US Fed chairman Jerome Powell raised the prospect of multiple ‘double-shot’ (50 basis point) rate hikes in 2022, adding that the first one could...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The study investigates NOX's flagship treatment, Veyonda, in combination with the chemotherapy drug doxorubicin for the treatment of patients with soft tissue sarcoma, an aggressive cancer in urgent need of new treatment options.

The company has a substantial arsenal of products and is channelling more funds into R&D to advance clinical trials, drug discovery and preclinical activities.

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

The clinical-stage drug development company is in a strong financial position following a recent R&D rebate, and is well-placed to advance a promising clinical pipeline.

The ASX has recovered following yesterday’s strong blow, closing up 1.29% with all 11 sectors finishing in the green on lower than normal trading volumes. Today’s biggest sector win was energy, up a nice 2.20% with the financial market foll...

Noxopharm (NOX) receives a $5.8 million cash refund under the Federal Government’s Research and Development rebate for FY21 The refund further strengthens its cash position from $23.6 million on September 30 The company says the refunded c...

The cash injection adds to Noxopharm’s robust cash position, which stood at A$23.6 million as of September 30, 2021.

The ASX is down -0.3% today with the information technology sector taking the cake for the biggest dip at ~3%, followed by the healthcare sector at more than 1.5%. The ASX Emerging Companies Index (XEC) has flatlined. For the second day in...

The ASX 200 Health Index (XHJ) is falling by 1.5% at the time of writing, compared to the broader index which is down by 0.30%. Two ASX-listed companies will be presenting at the annual H.C. Wainwright BIOCONNECT Virtual Conference, to be h...

The Noxopharm Ltd (ASX: NOX) share price has leapt 6% this morning after announcing a change in executive leadership. The move coincides with the drug development company’s goal to position itself on the global stage. At the time of writi...

“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next stages,” Dr Mautner said.

Noxopharm Limited (NOX) announces a shift in leadership in preparation for an upcoming ‘growth phase’ Dr Gisela Mautner has been appointed as CEO starting next month, with former CEO Dr Graham Kelly remaining on the board Dr Mautner joined...

Dow Jones hits fresh highs US stocks finished in mixed territories overnight. The Dow index rose 0.59%, but both S&P 500 and Nasdaq slumped by 0.06% and 1.33% respectively. Banks, industrials, and tech stocks led, following more evidenc...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The Noxopharm Ltd (ASX: NOX) share price is on the rise today after a clinical trial update. Noxopharm shares hit an intraday high of 39 cents, a 6.85% gain, before settling at 37 cents at the time of writing, up 1.37%. Noxopharm is a dru...

The ASX 200 Health Index (XHJ) is trading higher by 0.27% at the time of writing, compared to the broader index which is down by 0.40%. Fertility company Virtus Health (ASX:VRT) is being pursued by a takeover offer from BGH Capital. BGH, wh...

"This phase two study builds on our phase one trial, where we saw promising signals that it may be possible to achieve cancer reduction through the abscopal response,” says CMO.

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Noxopharm (NOX) signs licensing agreement with Hudson Institute of Medical Research for its cutting-edge ribonucleic acid (RNA) technology The licence is subject to clinical trials and marketing approvals for both RNA drug discovery and mR...

Amplia targets human trials for pancreatic cancer drug Noxopharm subsidiary enters licence agreement with Hudson Insitiute of Medical Research $7.2 million placement and $2 million SPP launched by Pharmaxis to support next phase of clinica...

RNA drugs already under development by Hudson will add to existing Pharmorage assets and help position the company at the forefront of chronic inflammatory/autoimmune diseases drug development.

The hot debut of Evolution Energy Minerals (ASX:EV1) was not enough to save the ASX resources sector from falling today. The ASX 200 finished 0.67% down at 7,420 points. All sectors were down except tech, which gained 0.18%. In contrast, mo...

The ASX posted steady gains to start the week on Monday, with investors preferences leaning towards tech/consumer stocks and gold (unusual bedfellows) at the expense of the big banks and iron ore majors. Companies that specialise in the pre...

“This grant not only provides substantial non-dilutive funding to Noxopharm, but it also lends external validation to our work. The MRFF awards a limited number of grants, funding only those projects that are highly rated against a series o...

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that its DARRT-2 Phase 2 clinical trial has commenced with patient enrolment in the US.

The company believes that DARRT-treatment has the potential to revolutionise cancer treatment by reducing cancer through the abscopal response without many of the unwanted side effects, cost limitations and logistical challenges associated...

Noxopharm (ASX:NOX) has received Notices of Allowance from patent offices in Australia and Europe covering the use of idronoxil (the active ingredient in Veyonda) as a chemo-enhancing drug.

“If we can improve the performance of ICIs by the addition of Veyonda, it could make a massive impact, improving outcomes for cancer patients worldwide. It is exciting that this study is now underway in Australia, and we look forward to upd...

Wall Street gains as Tesla breaks US$1 trillion market cap US stocks rose overnight, led by a surge in Tesla which ripped higher by over 12% after receiving an order of 100,000 vehicles from car rental company Hertz. Tesla has joined other...

The Noxopharm Ltd (ASX: NOX) share price is edging higher this afternoon and is currently trading up 2.8% at 55 cents apiece. Shares in the drug development company are on the move after it released a key announcement regarding its lead dr...

Noxopharm (NOX) is granted Australian and European patents for its use of Veyonda to achieve safer chemotherapy The patent allows dosages of chemotherapy to be lowered to safer levels through the company’s drug candidate without compromisi...

"A high proportion of cancer patients are deprived of the benefits of chemotherapies because of toxic side-effects. Other patients either are too ill or too elderly or just unwilling to even start chemotherapy. That is the gap that we see V...

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is higher by 0.7%. Notices from both the Australian and European Patent Offices have been received by Noxopharm (ASX:NOX), relating to...

The company is building a pipeline of drugs based on a unique and proprietary technology platform for large markets of unmet medical needs.

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US patent office has allowed claims relating to the use of a combination of its Veyonda and radiotherapy.

“We see the allowance of this patent application as a major win for the company in our goal of seeing DARRT therapy become a mainstream cancer treatment,” says CEO & MD.

The clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome is going into the new financial year in a strong cash position, enabling it to proceed with its exciting Four Pillars Oncology Prog...

Shares in drug company Noxopharm (ASX:NOX) climbed by around 4% this morning following the release of the company’s annual report. Along with the numbers, NOX also detailed the ongoing clinical development of Veyonda (idronoxil) as an adjuv...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

The discovery of idronoxil's anti-inflammatory mechanism adds a high-profile and potentially high-value drug target for the company’s subsidiary Pharmorage’s emerging pipeline.